FDA,VinayPrasad,andthequestionofregulatorydirectioninbiotech

One of my core investment theses was built on the assumption that an FDA under the Trump administration would act as a constructive partner to U.S. biotech innovation. I also believed Robert F Kennedy Jr.’s influence would tilt toward improving population health outcomes, even if his vaccine views remained controversial. In that framework, I expected friction but not structural obstruction.

What is unfolding instead is more complicated.

Vinay Prasad has emerged as a highly influential force within the FDA, and his regulatory stance is increasingly being viewed by parts of the industry as unusually restrictive. The reversal of the REPL committee’s position on Replimune, followed by internal disagreement over responsibility for the decision, has only added to the uncertainty. Reports suggest the initial recommendation favored approval, which was later overturned at higher levels of review.

Subsequent commentary around the composition of the second review panel has further intensified concerns, particularly allegations that it included members with prior critical positions toward the program. The resulting Complete Response Letter (CRL) has been widely viewed within biotech circles as unusually sharp in tone and interpretive in its framing of data. It is difficult to assess where responsibility ultimately sits across committee, reviewers, and leadership layers, but the broader signal to industry is one of increasing unpredictability in regulatory outcomes.

A similar dynamic is often referenced in the long-running challenges faced by ImmunityBio and Dr. Soon-Shiong. Anktiva remains a scientifically interesting immunotherapy platform with potential applications in oncology, yet its regulatory path has been unusually prolonged and complex relative to comparable therapies.

At a time when U.S. biotech has never been more scientifically advanced, there is growing concern that regulatory decision-making is becoming increasingly misaligned with the pace of innovation. Meanwhile, China continues to accelerate support for early-stage biotech development and clinical translation. This is not an argument against regulatory rigor safety standards are essential. However, the balance between caution and innovation is becoming the central question.

The U.S. biotech ecosystem has historically led global innovation because it combined capital, science, and regulatory clarity. If that equilibrium shifts too far, the consequence may not just be delayed approvals but a gradual migration of innovation itself.

Biotech is already one of the most capital-intensive and high-risk industries. The objective should be to strengthen scientific translation, not unintentionally slow it.